Search Results for: ANTIBODY DRUG CONJUGATES ADC Development
Articles
April 1, 2014
ANTIBODY DRUG CONJUGATES - ADC Development Using SMARTag(TM) Technology April 1, 2014
Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.
July 17, 2025
Gelteq Announces Agreement With IDT Australia to Secure Dedicated New Product Development & Manufacturing Facilities July 17, 2025
Gelteq Limited recently announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated,...
June 20, 2025
Veranova Devens Site Breaks Ground on ADC Facility Expansion June 20, 2025
Devens, MA, USA — Government officials, industry leaders, and local business representatives gathered yesterday to mark the groundbreaking of Veranova’s...
June 10, 2025
Adcendo ApS Announces First Patient Dosed in Phase 1/2 ADCElerate1 Trial of ADCE-D01 June 10, 2025
Adcendo recently announced the first patient has been dosed in the Phase 1/2 ADCElerate1 clinical trial evaluating ADCE-D01 in patients...
June 6, 2025
OBI Pharma Enters ADC Collaboration With TegMine Therapeutics Utilizing GlycOBI & TegMiner Enabling Technologies June 6, 2025
OBI Pharma, Inc. and TegMine Therapeutics, Inc. have entered into an ADC-related Master Services Agreement (MSA). Under the terms of...
June 4, 2025
SPECIAL FEATURE- Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure June 4, 2025
Contributor Cindy H. Dubin speaks with many CDMO professionals to get their insights and perspectives on the current state of the industry.
June 2, 2025
BioNTech & Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop & Co-Commercialize Next-Generation Bispecific Antibody Candidate Broadly for Multiple Solid Tumor Types June 2, 2025
BioNTech SE and Bristol Myers Squibb recently announced they have entered into an agreement for the global co-development and co-commercialization...
April 24, 2025
Avidicure Launches With $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer April 24, 2025
Avidicure recently announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from...
April 4, 2025
ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics April 4, 2025
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
April 3, 2025
EXECUTIVE INTERVIEW - Lonza: Driving Innovation & Sustainability: CDMO Trends & the Future of ADCs April 3, 2025
Sebastian Stenderup, Executive Director, Head of Commercial EMEA, Lonza, discusses some of the trends CDMOs are currently facing, from the growth of ADCs to the importance of sustainability, and how his company is responding to them.
March 4, 2025
Axplora Expands Commercial Payload Production Capabilities at Le Mans to Strengthen its Leading Position in ADC Manufacturing March 4, 2025
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the...
February 10, 2025
OUTSOURCING PHARMA DEVELOPMENT - Harnessing CDMOs for Innovation & Efficiency February 10, 2025
Rohtash Kumar, PhD, says a strategic partnership with a trusted CDMO can provide many benefits ranging from experts’ insights to state-of-the-art equipment. However, there are several considerations that developers should evaluate prior to engaging with a CDMO to maximize their partnership.
January 22, 2025
ArriVent BioPharma Enters Exclusive License With Lepu Biopharma for an Antibody Drug Conjugate for the Treatment of Gastrointestinal Cancers January 22, 2025
ArriVent BioPharma, Inc. recently announced it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code:...
November 12, 2024
Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform November 12, 2024
Araris Biotech AG recently announced the publication of a new technology for ADC generation that supports its foundational technology platform....
November 7, 2024
Lonza’s Synaffix Collaborates With BigHat Biosciences on the Development of a Machine Learning-Designed ADC November 7, 2024
Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with...
October 24, 2024
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates October 24, 2024
Lonza recently announced a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs....
October 8, 2024
Simtra BioPharma Solutions Expands Capabilities With $14M Investment in ADC Conjugation & Purification Clinical Suite October 8, 2024
Simtra BioPharma Solutions recently announced a $14-million investment to expand its clinical-scale conjugation and purification capabilities for Antibody-Drug Conjugates (ADCs)....
October 7, 2024
Cybrexa Therapeutics Announces First Patient Dosed With First-in-Class Peptide-Drug Conjugate in Phase 2 Trial in Ovarian Cancer October 7, 2024
Cybrexa Therapeutics recently announced the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in patients...
August 9, 2024
Abzena Supplies Clinical Trial Material for Angiex’s Phase 1 Study of First-in-Class TM4SF1-Directed ADC August 9, 2024
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, recently announced that patient dosing has begun for...
July 31, 2024
AC Immune Unveils Novel Therapeutic ADC Technology for Improved Efficacy in Neurodegenerative Diseases July 31, 2024
AC Immune SA recently unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer Antibody Drug Conjugate) in an...
